Cnr1−/− has minimal impact on chlorpyrifos-mediated effects in the mouse endocannabinoid system, but it does alter lipopolysaccharide-induced cytokine levels in splenocytes

• Published in: Chemico-biological interactions 2023-04, Vol.375, p.110425-110425, Article 110425
• Main Authors: Szafran, Brittany N., Nichols, James, Nicaise, Ashleigh, Borazjani, Abdolsamad, Carr, Russell L., Wilson, Juliet R., Ross, Matthew K., Kaplan, Barbara L.F.
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase - genetics; Acetylcholinesterase - metabolism; Animals; Cannabinoid receptor 1; Chlorpyrifos; Chlorpyrifos - toxicity; Cholinesterase Inhibitors - toxicity; Cytokines; Endocannabinoids; Female; Insecticides - toxicity; Lipopolysaccharides - toxicity; Mice; Organophosphates; Receptor, Cannabinoid, CB1 - genetics; Spleen - metabolism
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2023.110425

Chlorpyrifos (CPF) is an organophosphate pesticide that can inhibit endocannabinoid (eCB) metabolizing enzymes in animal models at levels that do not significantly alter acetylcholinesterase (AChE) in the central nervous system (CNS). Previous studies indicated that repeated low-level CPF exposure in developing rats increased the levels of eCBs in the brain. Because eCBs play a role in immune homeostasis through their engagement with cannabinoid receptors, we investigated the role of cannabinoid receptor 1 (CB1, encoded by the Cnr1 gene) on the CPF-mediated effects in the spleen and lung of neonatal and adult female mice. We treated neonatal and adult female Cnr1−/− mice with 2.5 mg/kg oral CPF or vehicle for 7 days. Tissues were harvested 4 h after the last CPF dose to evaluate eCB metabolic enzyme activity, levels of eCBs, and tissue immunophenotype. There were a small number of genotype-dependent alterations noted in the endpoints following CPF treatment that were specific to age and tissue type, and differences in eCB metabolism caused by CPF treatment did not correlate to changes in eCB levels. To explore the role of CB1 in CPF-mediated effects on immune endpoints, in vitro experiments were performed with WT murine splenocytes exposed to chlorpyrifos oxon (CPO; oxon metabolite of CPF) and challenged with lipopolysaccharide (LPS). While CPO did not alter LPS-induced pro-inflammatory cytokine levels, inactivation of CB1 by the antagonist SR141716A augmented LPS-induced IFN-γ levels. Additional experiments with WT and Cnr1−/− murine splenocytes confirmed a role for CB1 in altering the production of LPS-induced pro-inflammatory cytokine levels. We conclude that CPF-mediated effects on the eCB system are not strongly dependent on CB1, although abrogation of CB1 does alter LPS-induced cytokine levels in splenocytes. •CB1 did not play a big role in CPF-mediated changes in the lung or spleen.•In WT female SPLC, the CB1 antagonist enhanced LPS-induced IFN-γ.•In WT male SPLC, the CB1 antagonist modestly enhanced LPS-induced IFN-γ.•In male SPLC, there was enhanced LPS-stimulated IL-6 and IFN-γ in Cnr1−/− cells.